Prostascint discontinuation year?

When was Prostascint discontinued?

Prostascint (capromab pendetide) was discontinued in the United States in 2017.[1]

Was Prostascint permanently stopped, or can it still be found elsewhere?

The U.S. discontinuation refers to availability of the product in the United States. Availability in other countries can differ based on local regulatory decisions and supply, but the U.S. product was no longer marketed after 2017.[1]

What does “discontinued” usually mean for patients and clinicians?

After discontinuation, patients and providers generally cannot start new treatment/diagnostic courses using that specific commercial product, and use depends on whether any remaining stock exists and whether alternative imaging options are substituted in practice.[1]

What replaced Prostascint in clinical use?

After Prostascint’s U.S. discontinuation, clinicians typically used other prostate-cancer imaging approaches based on guideline and evidence, such as more current PSMA-targeted PET tracers, where available (these are distinct products from Prostascint).[1]

Sources

1. https://www.drugs.com/history/prostascint.html